Ghebremichael S, Svenson S B, Källenius G, Hoffner S E
Swedish Institute for Infectious Disease Control, Karolinska Institute, Stockholm, Sweden.
Scand J Infect Dis. 1996;28(4):387-90. doi: 10.3109/00365549609037925.
Clarithromycin and rifabutin are among the most promising drugs for the therapy of infections caused by Mycobacterium avium or other atypical mycobacteria. Since synergism of combined drugs is important in order to achieve strong antimycobacterial activity, the combined inhibitory effects of antibacterial agents should also be investigated when agents are evaluated for possible use in antimycobacterial drug therapy. In the present study we examined the antimycobacterial activity of clarithromycin, rifabutin, and their combination against 51 clinical isolates of the M. avium complex from patients with acquired immune deficiency syndrome (AIDS) with disseminated mycobacteriosis. A concentration-dependent inhibition was seen for each drug. The antibacterial effect was significantly more pronounced for the combined drugs than for the agents tested separately. Synergism, against up to 88% of the strains tested, was seen for the tested drugs combined at different concentrations. All 51 M. avium strains were susceptible to the combination of 4 mg/l clarithromycin and 2 mg/l rifabutin.
克拉霉素和利福布汀是治疗鸟分枝杆菌或其他非典型分枝杆菌引起的感染最有前景的药物之一。由于联合用药的协同作用对于实现强大的抗分枝杆菌活性很重要，因此在评估抗菌药物用于抗分枝杆菌药物治疗的可能性时，也应研究抗菌药物的联合抑制作用。在本研究中，我们检测了克拉霉素、利福布汀及其组合对51株来自获得性免疫缺陷综合征（AIDS）合并播散性分枝杆菌病患者的鸟分枝杆菌复合群临床分离株的抗分枝杆菌活性。每种药物均呈现浓度依赖性抑制作用。联合用药的抗菌效果明显比单独测试的药物更显著。在不同浓度下联合测试的药物对高达88%的测试菌株显示出协同作用。所有51株鸟分枝杆菌菌株均对4mg/l克拉霉素和2mg/l利福布汀的组合敏感。
